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BACKGROUND: Epothilones are a novel class of microtubule-stabilising agents, and sagopilone is a fully synthetic epothilone that has
shown marked in vivo and in vitro preclinical activity.
METHODS: This phase I, open-label study investigated the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of
weekly sagopilone. Twenty-three patients with malignancy resistant or refractory to standard treatment were enrolled into this study
evaluating sagopilone doses from 0.6 to 7.0mgm
 2.
RESULTS: The incidence of drug-related haematological adverse events (AEs) was low, with two grade 3 events observed.
Nonhaematological AEs were generally mild and reversible; increased g-GT was the only grade 4 event and grade 3 events
comprised peripheral neuropathy (n¼2), diarrhoea (n¼1) and fatigue (n¼1). Two grade 3 events were DLTs (diarrhoea and
peripheral neuropathy at 7.0mgm
 2). The MTD of weekly sagopilone was therefore established as 5.3mgm
 2. Stable disease was
the best overall response (n¼3). Microtubule bundle formation in peripheral blood mononuclear cells increased post-treatment,
peaking after 1h. Sagopilone disposition was similar across treatment courses and showed rapidly decreasing serum concentrations
after infusion end and a long terminal disposition phase with no obvious accumulation in the serum, probably reflecting a fast uptake
into tissues followed by a slow release.
CONCLUSION: Weekly administration of sagopilone could represent an alternative to the 3-weekly administration currently evaluated
in phase II trials.
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Microtubules are a well-established target for antineoplastic drugs,
and microtubule stabilisation by agents such as taxanes blocks cell
division and induces apoptosis. This has led to widespread use of
taxanes in cancer therapy (Goldspiel, 1997), although intrinsic or
acquired tumour resistance limit their benefits in many patients
(Horwitz et al, 1993).
The epothilones, a novel class of microtubule-stabilising agents,
have been developed following favourable microtubule stabilisa-
tion in vitro (Chou et al, 1998), ultimately leading to the
production of sagopilone, a fully synthetic epothilone (Klar et al,
2006), with high in vivo and in vitro activity and evasion of
p-glycoprotein efflux pumps (Klar et al, 2006; Hoffmann et al, 2008).
In this phase I trial, we evaluated the safety, tolerability and
pharmacokinetics of sagopilone in patients with heavily pretreated
solid tumours, to determine the maximum tolerated dose (MTD)
and dose-limiting toxicities (DLTs) of a weekly treatment schedule.
MATERIALS AND METHODS
Study design
This was a two-centre, open-label, phase I, non-randomised study
to determine the MTD and DLTs of weekly sagopilone adminis-
tration in patients with histologically confirmed malignancies.
Secondary objectives were to evaluate the safety, tolerability,
pharmacokinetics and pharmacodynamics of sagopilone. The
study was approved by the appropriate Independent Ethics
Committee and was conducted in accordance with the Declaration
of Helsinki and the ICH-GCP Guidelines of 17 January 1997.
Patient selection
Patients aged more than 18 years with histologically or cytologi-
cally confirmed malignancy that was resistant or refractory to
standard treatment were included further to informed consent.
Patients were required to have a World Health Organization
(WHO) performance status score of 0–2, an estimated life
expectancy of X3 months, and adequate haematological, hepatic,
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srenal and cardiac function. Patients were excluded from the study
if they had received biological therapy, chemotherapy or
immunotherapy within 4 weeks before enrolment, or radiation
therapy or major surgery within 2 weeks before enrolment.
Patients were also excluded if they had uncontrolled disease,
current peripheral neuropathy (National Cancer Institute (NCI)
common toxicity criteria grade 2), active metastatic brain disease
or primary brain tumours.
Treatment regimen
Sagopilone (10.5mg per vial or 5.5mg per vial lyophilised powder)
was supplied by Bayer Schering Pharma AG, Berlin, Germany.
For the 0.6mgm
 2 treatment group, one treatment course was
represented by six consecutive weekly 30-min intravenous
infusions, followed by a 3-week recovery period; in all other
treatment groups, one treatment course consisted of three
consecutive weekly intravenous infusions, followed by a 1-week
recovery period). The study protocol was amended after the
0.6mgm
 2 group was treated to produce a more practical
schedule, with shorter treatment periods and shorter, more
frequent recovery periods. Treatment was to continue until disease
progression or DLT (assessed after the first treatment course;
therefore, after either six or three sagopilone administrations
depended on the treatment group), with follow-up for 3 weeks
after the last treatment.
For dose escalation, a modified phase I 3þ3 Fibonacci design
starting at 0.6mgm
 2 body surface area was used and doses were
to be increased to 1.2, 1.8, 2.4, 4.0, 5.3, 7.0, 9.3 and 12.4mgm
 2 in
each successive treatment group. The choice of the 0.6mgm
 2
starting dose was based on in vivo toxicity studies (1 out of the 10
of the MTD from the most sensitive toxicity study). As the first
dose group was being completed, preliminary data from a parallel
study (Schmid et al, 2005) indicated that dose levels of
p12mgm
 2 every 3 weeks were well tolerated. The study protocol
was therefore amended to omit the 1.2, 1.8 and 2.4 doses and to
continue at an equivalent dose of 4.0mgm
 2. Dose-limiting
toxicity assessment was performed after each treatment course.
Once a patient had successfully completed an entire treatment
course (after either six or three sagopilone administrations
depended on the treatment group) and associated procedures,
they were eligible for dose escalation. Three evaluable patients
were required in each dose group, expanded to six evaluable
patients if a DLT was observed in one of the three original patients.
If a DLT was observed in two of the six patients in the expanded
group, dose escalation was terminated and the sample size of the
dose level below was increased to six patients. This lower dose was
considered to be the MTD if one or more of these six patients
experienced a DLT.
Safety and tolerability
Baseline safety assessments included a physical and neurological
examination, electrocardiogram (standard and digital 12-lead
Holter, Teltow, Germany), chest X-ray, WHO performance status,
vital signs, toxicity grading and collection of blood and urine
samples for laboratory examination. These assessments were
undertaken before every application of each treatment course
and at regular intervals throughout the treatment course. Data
were evaluated at the end of every treatment course. Toxicity and
adverse events (AEs) were recorded throughout treatment and
during follow-up and graded using the NCI/National Institute of
Health Common Toxicity Criteria version 2.0.
Pharmacodynamics and efficacy
Tumour evaluation was performed using WHO/International
Union Against Cancer (UICC) criteria for patients with measurable
disease between days 43 and 50 of each treatment course for the
0.6mgm
 2 treatment group, or between day 22 of the previous
course and the first day of the subsequent treatment course for
other dose levels. Tumour markers could be considered as
evidence of measurable disease in prostate cancer (prostate-
specific antigen) and in ovarian cancer (CA-125). Microtubule
bundle formation in peripheral blood mononuclear cells (PBMCs)
was visualised by immunofluorescent staining using 8ml blood
samples taken before, and 1 and 24h after the end of drug
administration at the first and third application of the first
treatment course. Immunofluorescent staining was performed by
HistoGeneX (Edegem, Belgium) using a method similar to that
previously described (McDaid et al, 2002).
Pharmacokinetics
Blood samples for pharmacokinetic analysis were taken during all
applications in the first treatment course at baseline, then 5 and
15min after infusion start and just before infusion end at 30min.
Further samples were collected at 5, 15, 30 and 60min, and 2, 3, 5,
10, 24, 48, 72 and 96h after the end of each infusion and 168h after
the end of the third infusion. For subsequent treatment courses,
sampling was performed at baseline, 72h after the end of infusion
and 168h after the end of the third infusion. Sagopilone serum
concentrations were determined by validated liquid chromatogra-
phy/mass spectrometry with a 0.1ngml
 1 lower limit of quantita-
tion. Pharmacokinetic evaluation was based on individual
sagopilone serum concentration/time values, and parameters were
calculated using the Kinetica software tool (Thermo Fisher
Scientific, Philadelphia, PA, USA) without recourse to model
assumptions. Individual treatment courses were only included in
evaluations if X1 valid point was available to assess maximum
serum concentration (Cmax). If X1 measurement was available
during infusion, but not after infusion, Cmax and area under the
curve (AUC) measurements were estimated but not included in the
statistical analysis. For the calculation of pharmacokinetic para-
meters other than Cmax and tmax, X3 consecutive data points were
required.
Statistical analysis
Descriptive statistics were used and the number of patients, mean,
s.d. and range were calculated for the relevant variables. For
pharmacodynamics assessments, repeated-measurement models
evaluating the relationship of microtubule bundling (percentage of
affected PBMCs) with time point or dosage (mgm
 2) were
calculated with PROC GLM in SAS (v 9.1; SAS Institute Inc., Cary,
NC, USA).
RESULTS
Patient characteristics
Of 24 patients screened at two German centres, 23 were enrolled
in the study between January 2004 and November 2005. All 23
patients received treatment and were evaluable for safety, 20
patients comprised the per-protocol set and 11 patients had
samples evaluable for pharmacokinetics. Patients with a variety of
primary tumour types, including pleural mesothelioma, colorectal
cancer, renal cell cancer, breast cancer and choroidal melanoma,
were enrolled in the study (Table 1). Most patients (87%) had a
WHO status p1 at baseline. Patients had undergone a high level
of pretreatment; 96% of patients had received previous chemo-
therapy, including previous taxane treatment in 43% and previous
cytokine treatment in 4%. The median (range) number of previous
chemotherapy regimens was 4 (1–14). Eight patients had previ-
ously received radiotherapy, whereas 16 patients had undergone
earlier surgery. Despite this level of pretreatment, patients had no,
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sor a low, response to earlier therapy (the majority classified as
progressive disease).
Treatment and dosing
Of the 23 patients who received study treatment, nine were
assigned to the 0.6mgm
 2 dose, three to the 4mgm
 2 dose, seven
to the 5.3mgm
 2 dose and four to the 7.0mgm
 2 dose. Two
patients completed the study as planned, one patient receiving four
and the other six treatment courses (12 and 18 sagopilone
administrations, respectively), whereas 21 patients discontinued
study treatment prematurely (receiving a median of 6 (range 2–18)
sagopilone infusions). Of these, 14 withdrew because of disease
progression, six because of AEs and one withdrew consent. Nine
patients were recruited to the 0.6mgm
 2 dose group to have three
patients that were evaluable for dose-escalation analysis. Of these
nine patients, three accidentally received a reduced dose of
sagopilone because of a drug preparation error in the pharmacy
and were therefore excluded from the per-protocol population.
Seven courses (6-weekly sagopilone treatments followed by a
3-week recovery phase) were received in the 0.6mgm
 2 dose
group, with a median (range) of 1 (0–2), and 28 courses (3-weekly
sagopilone treatments followed by 1-week recovery) were admi-
nistered in the 4.0–7.0mgm
 2 dose groups with a median (range)
of 2 (0–6).
No DLTs were reported at doses 0.6–5.3mgm
 2. Two DLTs
were observed at 7.0mgm
 2: grade 3 diarrhoea and grade 3
peripheral neuropathy, experienced by one patient each (Table 2).
Additional patients were therefore assigned to the lower-dose
group (5.3mgm
 2) to a total of six evaluable for DLT analysis
(one patient was not evaluable). The MTD was established as
5.3mgm
 2 and the highest dose given to patients was 7.0mgm
 2.
Tolerability
The incidence of drug-related haematological AEs was low, with
no grade 4 events and one patient each experiencing grade 3
lymphopenia and thrombocytopenia (0.6mgm
 2 dose) (Tables 2
and 3). Correlation of haematological AEs with serum saglopilone
concentration was not possible due to the limited availability of
serum samples. Drug-related nonhaematological AEs were
generally mild and reversible (Tables 2 and 3) with grade 3 events,
including DLTs detailed above, reported in only four patients
(peripheral neuropathy in one patient each in the 5.3 and
7.0mgm
 2 groups, and diarrhoea and fatigue in one patient each
at 7.0mgm
 2 sagopilone) (Table 2). One patient had a grade 4
event (increase in g-GT at 7.0mgm
 2 sagopilone). Peripheral
neuropathy was the most clinically relevant nonhaematological AE,
reported in 10 patients (43.5%; one patient experienced both
polyneuropathy and hypoesthesia) and considered a DLT in one
patient (Tables 2 and 3). The estimated median time to neuropathy
onset was 18 days. At baseline, nine patients had grade 1 peripheral
neuropathy, five of whom had previous taxane treatment. During
this study, the majority of the peripheral neuropathy events
observed were grades 1 and 2 (eight patients), and no grade 4
events were reported. Grades 1 and 2 treatment-related nausea and
vomiting were observed in 22 and 17% of patients, respectively
(Table 3). The only occurrence of diarrhoea was as a DLT (grade 3)
Table 1 Patient demographics, disease status and earlier neoplastic treatment
Characteristic 0.6mgm
 2 (n¼9) 4.0mgm
 2 (n¼3) 5.3mgm
 2 (n¼7) 7.0mgm
 2 (n¼4)
Age, n
Mean 52 41 55 41
Range 44–65 33–68 48–67 25–70
Sex, n
Female 3 3 3 2
Male 6 0 4 2
WHO performance
status, n
05 1 2 2
14 1 4 2
20 1 1 0
Tumour types Pancreatic cancer (two
patients), retroperitoneal
cancer, breast cancer, colon
cancer, thymus cancer, choroid
melanoma, adrenal gland
cancer, peritoneal cancer
Urothelial cancer,
cholangiocellular
carcinoma, renal sarcoma
Pancreatic cancer, pleural
mesothelioma (two patients),
gallbladder carcinoma, fallopian
tube cancer, renal cell
carcinoma, rectal cancer
Gallbladder carcinoma, cancer
of unknown primary origin,
oesophageal cancer, epithelioid
sarcoma
Previous therapy, n
Chemotherapy 9 3 6 4
Taxanes 4 1 3 2
Immunotherapy 2 1 3 1
Hormone therapy 1 0 1 0
Radiotherapy 5 1 1 1
Surgery 6 3 5 2
Number of earlier
chemotherapy regimens, n
00 0 1 0
11 0 1 0
22 1 3 1
31 1 0 0
42 0 0 0
X53 1 2 3
Weekly sagopilone in patients with refractory solid tumours
D Arnold et al
1243
British Journal of Cancer (2009) 101(8), 1241–1247 & 2009 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sat 7.0mgm
 2 sagopilone (Table 2). No hypersensitivity reactions
were reported, despite the lack of premedication, and no patients
died while receiving sagopilone treatment.
Pharmacodynamics and efficacy
Post-treatment tumour evaluation data are available for 11
patients; 12 patients were excluded due to incorrect dosing and
absence of post-treatment data (2 patients and 10 patients,
respectively). No objective responses were observed in this heavily
pretreated population and stable disease was the best overall
response, reported in three patients: one with cholangiocellular
carcinoma (4.0mgm
 2 dose), and one each with fallopian tube
cancer and pleural mesothelioma (5.3mgm
 2 dose). Follow-up
data were available for 10 patients in groups 4.0–7.0mgm
 2, and
of the patients who achieved stable disease, the median (range) of
stable disease duration was 68.5 (23–162) days.
Complete data sets (pre-dose, 1h post-dose and 24h post-dose
samples evaluable) of PBMC tubulin immunofluorescent staining
were available for 19 patients. Peripheral bundle formation was
increased in post-treatment PBMC samples taken during the first
treatment course (Figure 1A, B) and was highest 1h after treatment
application (Figure 1C), reaching a maximum overall mean±s.d.
increase from pre-dose levels of 7.61±10.15% for the first
sagopilone application. This was also observed to a lesser extent
for the third sagopilone application of the first course, with a
maximum overall mean ±s.d. increase from pre-dose levels of
5.84±7.40%. A repeated-measurement model indicated that the
time of sample collection, but not the dose level, was related to
the degree of tubulin bundle formation (P¼0.0058 and 0.2299,
respectively).
Pharmacokinetics
Pharmacokinetic data are available for 11 patients. Mean
pharmacokinetic parameters are presented for the 4.0 and
5.3mgm
 2 treatment groups only, as data from only one and
two patients were available for the 0.6 and 7.0mgm
 2 groups,
respectively (Table 4). The largest number of evaluable patients
(n¼6) were in the 5.3mgm
 2 group. For treatment cycles 1 and 3,
the mean AUC (0–tlast) was between 153 and 157ngh
 1ml
 1, the
mean terminal elimination half-life (t1/2) ranged from 33 to 58h,
the mean total body clearance was between 1000 and
1359mlmin
 1, and the mean volume of distribution at steady
state (Vss) ranged from 1851 to 4852l (Table 4). The large
distribution volume indicates high tissue and/or tubulin binding.
The mean concentration–time profile of sagopilone showed a
multiexponential disposition (Figure 2). Sagopilone serum con-
centrations decreased to o10% peak concentration by 10h after
infusion end, followed by a long terminal disposition phase. The
pharmacokinetics of sagopilone at the 5.3mgm
 2 dose were
similar during these three applications. No obvious differences in
the pharmacokinetics (e.g., Cmax or AUC) could be seen between
treatment courses, suggesting that no or only minimal accumula-
tion occurred. Owing to small sample sizes and methodological
difficulties related to the collection of plasma samples, any
Table 3 Grades 1 and 2 drug-related adverse events (AEs)
AE
0.6mgm
 2,
n (n¼9)
4.0mgm
 2,
n (n¼3)
5.3mgm
 2,
n (n¼7)
7.0mgm
 2,
n (n¼4)
Overall,
n (%) (n¼23)
Haematological AEs
Lymphopenia 1 1 1 3 (13)
Decreased haemoglobin 1121 5 (22)
Nonhaematological AEs
Nausea 2111 5 (22)
Vomiting 2 1 1 4 (17)
Constipation 1 1 2 (9)
Abdominal pain 2 2 (9)
Peripheral neuropathy 4121 8 (35)
Hyperesthesia 1 1 (4)
Asthenia 1 1 (4)
Eye irritation 1 1 (4)
Headache 1 1 (4)
Intention tremor 1 1 (4)
Mucosal inflammation 1 1 (4)
Peripheral oedema 1 1 (4)
Pyrexia 1 1 (4)
Subileus 1 1 (4)
Temperature intolerance 1 1 (4)
Table 2 Grade X3 drug-related adverse events and dose-limiting toxicities
Adverse event
0.6mgm
 2,
n (n¼9)
4.0mgm
 2,
n (n¼3)
5.3mgm
 2,
n (n¼7)
7.0mgm
 2,
n (n¼4)
Overall,
n (n¼23)
Peripheral neuropathy 11
a 2 (9)
Diarrhoea 1
a 1 (4)
Fatigue 1 1 (4)
Increased g-GT 1
b 1 (4)
Lymphopenia 1 1 (4)
Thrombocytopenia 1 1 (4)
aDose-limiting toxicities; all events grade 3 except grade 4.
bGrade 4.
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correlation to dose linearity or relationships between sagopilone
serum concentrations and microtubule binding in PBMCs could
be drawn.
DISCUSSION
In this phase I dose-escalation study, weekly sagopilone
administration was well tolerated in heavily pretreated patients
with solid tumours. Two DLTs, one case each of grade 3 peripheral
neuropathy and grade 3 diarrhoea, were observed at 7.0mgm
 2
and the MTD was determined as 5.3mgm
 2. The incidence of
diarrhoea associated with sagopilone use is generally low, with a
similar phase I trial evaluating a once-every-3-week regimen of
sagopilone administration recently reporting an MTD of
22mgm
 2, and a low incidence of diarrhoea (Schmid et al, 2005).
Peripheral neuropathy was the most clinically relevant AE and a
DLT in one patient. This was not an unexpected finding in
a heavily pretreated study population as neuropathy can be a
cumulative toxicity from many chemotherapy compounds, and is
a common AE in patients treated with microtubule-stabilising
agents (Marupudi et al, 2007). Despite pretreatment with taxanes
in 10 patients and grade 1 peripheral neuropathy in nine patients
at baseline, the overall incidence of peripheral neuropathy in this
investigation was moderate, with only two grade 3 events and no
grade 4 events. There was no correlation between cumulative
peripheral neuropathy and earlier taxane use; this ensures the
MTD results from sagopilone administration alone and not a
combination of sagopilone and earlier taxane use. However, as
some patients may have not received several courses of earlier
taxane therapy, there still remains some uncertainty in precise
assessment of cumulative toxicity such as neuropathy.
The second DLT observed, grade 3 diarrhoea, affected only one
patient. Diarrhoea has rarely been reported with sagopilone
treatment, although it is a DLT of patupilone and is frequently
observed with ixabepilone (Low et al, 2005; Rubin et al, 2005).
Nausea and vomiting were mild-to-moderate and easily manage-
able with standard antiemetics. The incidence of haematological
events was low, consistent with the other phase I sagopilone trial
(Schmid et al, 2005) but in contrast to that seen with ixabepilone
therapy, which has neutropenia as a DLT (Zhuang et al, 2005).
No objective responses were observed in this heavily pretreated
population with tumours resistant to many anticancer treatments.
This observation is unsurprising considering the small sample size
and medical history of the population. Stable disease was the best
response observed in three patients, one of whom had fallopian
tube cancer refractory to four previous chemotherapy regimens,
notably including paclitaxel.
Microtubule bundle formation in PBMCs is a marker of the
ability of a microtubule-stabilising drug to bind to its target in vivo
and induce tubulin polymerisation (Horwitz et al, 1993). Tubulin
polymerisation was highest in samples taken 1h after sagopilone
infusion, indicating that sagopilone rapidly induces in vivo
microtubule binding with a similar time course to that reported
for ixabepilone (McDaid et al, 2002; Mani et al, 2007). The
reduction of bundle formation seen 24h post-dose may indicate
that this binding process is reversible and/or may be due to the
rapid clearance of sagopilone from the circulatory system.
In patients receiving 5.3mgm
 2 sagopilone, the pharmaco-
kinetics of sagopilone were similar across each treatment cycle and
course. The rapid initial decrease in serum concentrations after the
end of infusion was possibly due to fast uptake of sagopilone into
tissues. The long t1/2 most likely reflects the release of sagopilone
from deep tissue compartments, rather than the rate of meta-
bolism or excretion. This rapid uptake and slow release from
tissues supports data from preclinical sagopilone research
(Hoffmann et al, 2008).
Owing to the limited sample size, these pharmacokinetic
conclusions should be interpreted with caution as, unfortunately,
in some patients the intended blood sampling did not occur, for
example, blood samples may have been taken a few minutes after
the end of sagopilone infusion, as opposed to shortly before the
end of infusion. Therefore, the rapid elimination of sagopilone
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Figure 1 Visualisation of microtubule bundle formation in peripheral
blood mononuclear cells in a patient sample from the 7.0mgm
 2 dose
group (A) before treatment, (B) 1h after drug application and (C)
microtubule bundle formation over time with sagopilone treatment before
1h and 24h after the first application of sagopilone during the first
treatment course.
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and the small samples size available was not able to overcome
these operational challenges.
This study shows that 5.3mgm
 2 sagopilone administered
weekly is feasible and well tolerated. However, the 3-weekly
administration reported by Schmid et al (2005), with an MTD of
22mgm
 2, was considered to be the preferable regimen due to its
tolerability profile and more convenient dosing schedule.
Encouraging results from both phase I trials have led to a broad
phase II programme, with ongoing trials using the 3-weekly
schedule in several indications, including prostate, ovarian, breast
and lung cancer, glioblastoma and melanoma. Proof-of-concept
has been established for sagopilone in platinum-resistant (Rustin
et al, 2007a) and platinum-sensitive (McMeekin et al, 2008)
ovarian cancer, melanoma (Wenk et al, 2008) and androgen-
independent prostate cancer (Graff et al, 2008). Results from
additional trials will provide further evidence of the clinical
potential of sagopilone.
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Figure 2 The mean concentration–time profile of sagopilone adminis-
tered weekly at 5.3mgm
 2 over three treatment cycles.
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